PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › HLX07

Drugs in development · updated 30 October 2026

HLX07: clinical trials and development status

NLM verified identityNot approved in the USNo EMA authorisationEstimated launch Mar 2031 – Jan 2032 (Phuturdex estimate)

As of 30 October 2026 HLX07 is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 1 diseases. The most advanced phase is II–III.

4Active trials
II–IIIMost advanced phase
1Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow HLX07 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Colonic neoplasmI–II1NCT07358585

Everything on HLX07

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch